본문 바로가기
KERD
논문KCI 등재

Ospemifene: A Novel Option for the Treatment of Vulvovaginal Atrophy

이정렬|김슬기|서창석|신재준
대한폐경학회 (Korean Society Of Menopause)|2017.08|대한폐경학회지 (Journal of Menopausal Medicine)|제23권 제2호|pp. 79-84

1

조회

0

다운로드

1

인용

0

참고문헌

초록

Ospemifene—a third-generation selective estrogen receptor modulator approved by the Food and Drug Administration in 2013—is an oral medication for the treatment of dyspareunia. In postmenopausal women with vulvovaginal atrophy, ospemifene significantly improves the structure and pH levels of the vagina, reducing dyspareunia. It is available as a 60-mg tablet; hence, women who may have had prior difficulty with vaginal administration or on-demand use of nonprescription lubricants and moisturizers would likely prefer this form of treatment. Preclinical studies demonstrated that ospemifene has an estrogen agonist action on the bone, reducing the cell proliferation of ductal carcinoma in an in situ model. Studies evaluating the safety of treatment for up to 52 weeks have shown that ospemifene is a safe medication with minimal impact on the endometrium. Further studies with larger number of subjects are necessary to better conclude its effects and long-term safety. (J Menopausal Med 2017;23:79-84)

Abstract

Ospemifene—a third-generation selective estrogen receptor modulator approved by the Food and Drug Administration in 2013—is an oral medication for the treatment of dyspareunia. In postmenopausal women with vulvovaginal atrophy, ospemifene significantly improves the structure and pH levels of the vagina, reducing dyspareunia. It is available as a 60-mg tablet; hence, women who may have had prior difficulty with vaginal administration or on-demand use of nonprescription lubricants and moisturizers would likely prefer this form of treatment. Preclinical studies demonstrated that ospemifene has an estrogen agonist action on the bone, reducing the cell proliferation of ductal carcinoma in an in situ model. Studies evaluating the safety of treatment for up to 52 weeks have shown that ospemifene is a safe medication with minimal impact on the endometrium. Further studies with larger number of subjects are necessary to better conclude its effects and long-term safety. (J Menopausal Med 2017;23:79-84)

참고문헌 (36)

  1. Calleja-Agius J, "Urogenital atrophy", Climacteric, 12, pp.279~285 (2009)
  2. Levine KB, "Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women", Menopause, 15, pp.661~666 (2008)
  3. Santoro N, "Prevalence and impact of vaginal symptoms among postmenopausal women", J Sex Med, 6, pp.2133~2142 (2009)
  4. 김석환, "Rejuvenation Using Platelet-rich Plasma and Lipofilling for Vaginal Atrophy and Lichen Sclerosus", 대한폐경학회지, 23(1), pp.63~68 (2017), 대한폐경학회
  5. Burich R, "Current treatment options for vulvovaginal atrophy", Expert Rev Obstet Gynecol, 6, pp.141~151 (2011)
  6. 박형무, "승마 (black cohosh)와 St. John's wort 복합제 (훼라민-큐？)의 갱년기 증상에 대한 효과: 다기관 무작위 이중맹검 위약대조 임상연구", Obstetrics & Gynecology Science, 48(10), pp.2404~2413 (2005), 대한산부인과학회
  7. 홍성남, "폐경기 여성에서 승마 물질의 비뇨기 위축과 부작용에 대한 효과", 대한폐경학회지, 18(2), pp.106~112 (2012), 대한폐경학회
  8. Kim M, "Changes in atrophic symptoms, the vaginal maturation index, and vaginal pH in postmenopausal women treated with vaginal estrogen tablets", J Korean Soc Menopause, 16, pp.162~169 (2010)
  9. Davies GC, "Adverse events reported by postmenopausal women in controlled trials with raloxifene", Obstet Gynecol, 93, pp.558~565 (1999)
  10. Gennari L, "Ospemifene use in postmenopausal women", Expert Opin Investig Drugs, 18, pp.839~849 (2009)
  11. Qu Q, "Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats", Endocrinology, 141, pp.809~820 (2000)
  12. Goldstein SR, "Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy", Climacteric, 17, pp.173~182 (2014)
  13. Koskimies P, "Single-dose and steady-state pharmacokinetics of ospemifene, a selective estrogen receptor modulator, in postmenopausal women", Int J Clin Pharmacol Ther, 51, pp.861~867 (2013)
  14. Unkila M, "Vaginal effects of ospemifene in the ovariectomized rat preclinical model of menopause", J Steroid Biochem Mol Biol, 138, pp.107~115 (2013)
  15. Kangas L, "Tissue selectivity of ospemifene: pharmacologic profile and clinical implications", Steroids, 78, pp.1273~1280 (2013)
  16. Hellmann-Blumberg U, "Genotoxic effects of the novel mixed antiestrogen FC-1271a in comparison to tamoxifen and toremifene", Breast Cancer Res Treat, 60, pp.63~70 (2000)
  17. Burich RA, "Ospemifene and 4-hydroxyospemifene effectively prevent and treat breast cancer in the MTag.Tg transgenic mouse model", Menopause, 19, pp.96~103 (2012)
  18. Taras TL, "In vitro and in vivo biologic effects of Ospemifene (FC-1271a) in breast cancer", J Steroid Biochem Mol Biol, 77, pp.271~279 (2001)
  19. Wurz GT, "Ospemifene inhibits the growth of dimethylbenzanthracene-induced mammary tumors in Sencar mice", J Steroid Biochem Mol Biol, 97, pp.230~240 (2005)
  20. Wurz GT, "Pharmacologic effects of ospemifene in rhesus macaques: a pilot study", Basic Clin Pharmacol Toxicol, 102, pp.552~558 (2008)
  21. Bachmann GA, "Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study", Menopause, 17, pp.480~486 (2010)
  22. Simon JA, "One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus", Menopause, 20, pp.418~427 (2013)
  23. Simon J, "Long-term safety of ospemifene (52-week extension) in the treatment of vulvar and vaginal atrophy in hysterectomized postmenopausal women", Maturitas, 77, pp.274~281 (2014)
  24. Portman DJ, "Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy", Menopause, 20, pp.623~630 (2013)
  25. Cui Y, "The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-analysis", J Sex Med, 11, pp.487~497 (2014)
  26. McCall JL, "Pharmacologic evaluation of ospemifene", Expert Opin Drug Metab Toxicol, 6, pp.773~779 (2010)
  27. Portman D, "Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial", Maturitas, 78, pp.91~98 (2014)
  28. Nappi RE, "The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy", Climacteric, 18, pp.233~240 (2015)
  29. Qu Q, "Comparative effects of estrogen and antiestrogens on differentiation of osteoblasts in mouse bone marrow culture", J Cell Biochem, 73, pp.500~507 (1999)
  30. Stuenkel CA, "Treatment of symptoms of the menopause: an endocrine society clinical practice guideline", J Clin Endocrinol Metab, 100, pp.3975~4011 (2015)
  31. Rutanen EM, "Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a doubleblind, randomized trial", Menopause, 10, pp.433~439 (2003)
  32. Komi J, "Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women", Menopause, 12, pp.202~209 (2005)
  33. Ylikorkala O, "Effects of ospemifene, a novel SERM, on vascular markers and function in healthy, postmenopausal women", Menopause, 10, pp.440~447 (2003)
  34. David F. Archer, "Ospemifeneʼs effects on lipids and coagulation factors", Menopause, 24(10), pp.1167~1174 (2017), Ovid Technologies (Wolters Kluwer Health)[DOI]
  35. Shionogi Inc, "Osphena®: prescribing package insert" (2015), Shionogi Inc
  36. Lehtinen T, "Effects of cytochrome P450 inhibitors and inducers on the metabolism and pharmacokinetics of ospemifene", Biopharm Drug Dispos, 34, pp.387~395 (2013)

관련 논문AI추천

Therapeutic Approaches to Atrophic Vaginitis in Postmenopausal Women: A Systematic Review with a Network Meta-analysis of Randomized Controlled Trials김태희, 이해혁, Arum Lee, Bora Lee, Kisung Song, Temuulee Enkhbold, Yeon-Suk Kim, Yoo Jin Park대한폐경학회 · 대한폐경학회지2018 · 제24권 제1호Updates on Therapeutic Alternatives for Genitourinary Syndrome of Menopause: Hormonal and Non-Hormonal Managements김미란, CHUNG YOUN JEE, Kyung-Min Park, Suhyun Shim대한폐경학회 · 대한폐경학회지2021 · 제27권 제1호Clinical Efficacy of Hormonal and Nonhormonal Agents in the Treatment of Vulvovaginal AtrophyArif Serhan Cevrioglu, Gokcen Ilhan, Mehmet Musa Aslan, Muzaffer Yıldırım, Unal Erkorkmaz대한폐경학회 · 대한폐경학회지2021 · 제27권 제1호Early Effect of 0.005% Estriol Vaginal Gel on Symptoms and Signs of Vulvovaginal AtrophyCuerva González Marcos, Cuevas Castillo Carmen, Delgado Marín Juan Luis, González Rodríguez Silvia, Lázaro-Carrasco de la Fuente Jesús, Nieto Magro Concepción대한폐경학회 · 대한폐경학회지2022 · 제28권 제2호Treatment of Genitourinary Syndrome of Menopause in Breast Cancer and Gynecologic Cancer Survivors: Retrospective Analysis of Efficacy and Safety of Vaginal Estriol, Vaginal Dehydroepiandrosterone and OspemifeneAndrea Morciano, Benedetto Ferraresi, Ermelinda Pennacchini, Lorenzo Campanella, Marzio Angelo Zullo, Matilde Marinelli, Mauro Cervigni, Michele Carlo Schiavi, Pier Luigi Palazzetti, Roberta Dall’Alba, Silvia Iapaolo대한폐경학회 · 대한폐경학회지2024 · 제30권 제3호Efficacy and Safety of Intravaginal Estrogen in the Treatment of Atrophic Vaginitis: A Systematic Review and Meta-AnalysisAbraish Ali, Aliha Iftikhar, Eesha Baig, Mahnoor Humayun, Mahnoor Rehan Hashmi, Muhammad Saad, Muhammad Usama Shaid, Muzainah Tabassum, Rayaan Imran, Sidra Imtiaz대한폐경학회 · 대한폐경학회지2024 · 제30권 제2호

이 간행물의 다른 논문 (9건)

Risk Assessment: Factors Contributing to Discomfort for Menopausal Women in WorkplaceBahar Seifi, Mehdi Jafari, Mohammad Heidaripp. 85-90The Effect of Educational Program on Quality of Life in Menopausal Women: A Clinical TrialEnsiyeh Jenabi, Fatemeh Shobeiri, Seyyed Mohammad Mahdi Hazavehei, Ghodratollah Roshanaei, Mahnaz Khatibanpp. 91-95The Relationship between Renal Function and Bone Marrow Density in Healthy Korean Women최욱환, 박병규, 김승철, 주종길, 윤가영, 이규섭pp. 96-101A Survey of Osteoporosis and Breast Cancer Risk Perception among Menopausal and Postmenopausal Women in Hong KongLouis WC Chow, Ivy CF Li, Jennifer WJ Chu, Michael MC Cheungpp. 102-107Effects of Group Counseling on Self-care Behaviors in Menopausal Women with DiabetesParisa Parsa, Manoocher Karami, Nasrin Khorami, Farzaneh Soltani, Roya Ahmadinia Tabeshpp. 108-116
원문 보기